ClinicalTrials.gg
CompletedNCT04295772Updated Jan 31, 2024Results posted

Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)

A Phase 2 interventional study of DOR/ISL in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 17 sites in 5 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2024-01-31.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
Up to 17 Years
Sex
All
01

Study summary

This is a phase 2, single-group, multi-site, open-label study of an islatravir/doravirine (ISL/DOR, MK-8591A) fixed dose combination (FDC) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric participants who are virologically suppressed (VS) on antiretroviral therapy (ART) for ≥3 months or are treatment-naive (TN). The primary purposes of the study are 1) to examine the steady-state pharmacokinetics (PK) of ISL in plasma; 2) the steady-state PK of ISL-triphosphate (ISL-TP) in peripheral blood mononuclear cells (PBMCs); and 3) to examine the safety and tolerability of ISL/DOR.

Read the detailed description

As of protocol amendment 03 (approved 08-Feb-2022), all participants have been discontinued from study therapy and will be switched to non-study antiretroviral therapy and monitored for safety. The present results cover data obtained through the cut-off date of 30-Mar-2022, and will be updated once monitoring is completed.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is -1 positive, is \<18 years of age, and weighs ≥35 kg at screening.
  • VS Participants: Is HIV-1 positive at Screening with plasma HIV-1 RNA \<50 copies/mL and has been receiving continuous, stable oral 2-drug or 3-drug combination ART ± PK booster with documented viral suppression for ≥3 months prior to providing documented /assent and has no history of prior virologic treatment failure on any past or current regimen.
  • TN Participants: Is HIV-1 positive at Screening with plasma HIV-1 RNA ≥500 copies/mL and is naive to ART defined as having received \<=10 days of prior therapy with any antiretrovirals following HIV-1 diagnosis other than pre-exposure prophylaxis (PrEP) or potentially exposed person (PEP).
  • If female, is not pregnant or breastfeeding, and is either 1) not a woman of (WOCBP) or 2) is a WOCBP and is using acceptable or is abstinent.

Exclusion criteria

Exclusion Criteria:

  • Has -2 infection.
  • Has or other to any of the components of the study drugs as determined by the investigator.
  • Has an active diagnosis of hepatitis due to any cause, including active virus (HBV) infection (defined as hepatitis B surface antigen [HBsAg]-positive or HBV deoxyribonucleic acid [DNA] positive).
  • Has a history of ≤5 years prior to providing documented except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma.
  • Has a history or current evidence of any condition (including active tuberculosis infection), therapy, laboratory abnormality or other circumstance (including drug or alcohol use or dependence) that might, in the opinion of the investigator, confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate.
  • Is taking or is anticipated to require systemic therapy, immune modulators, or any prohibited therapies from 45 days prior to Day 1 through the study treatment period.
  • Is currently taking long-acting cabotegravir-rilpivirine.
  • Is currently participating in or has participated in an interventional clinical study with an compound or device from 45 days prior to Day 1 through the study treatment period.
  • Has a documented or known virologic resistance to DOR/ISL (DOR resistance substitutions in reverse transcriptase: V106A/M, V108I, Y188L, H221Y, P225H, F227C/L, M230I/L, L234I, P236L, or Y318F; ISL resistance substitution in reverse transcriptase: M184V/I).
  • Has exclusionary laboratory values.
  • Is female and expecting to conceive or donate eggs at any time during the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    DOR/ISL

    Pediatric participants with HIV-1 infection receive DOR/ISL for 96 weeks.

    Drug: DOR/ISL

Interventions

  • DrugDOR/ISL

    Drug pages: Doravirine · Islatravir

    100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.

    Also known as: MK-8591A, Doravirine/islatravir

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Drug Concentration-time Curve From 0 to 24 Hours Post-dose (AUC0-24) of Islatravir (ISL)

    The AUC0-24 of ISL in plasma was determined at steady state.

    Time frame: Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28

  2. Maximum Plasma Concentration (Cmax) of ISL

    The Cmax of ISL in plasma was determined at steady state.

    Time frame: Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28

  3. Time to Reach Maximum Plasma Concentration (Tmax) of ISL

    The Tmax of ISL in plasma was determined at steady state.

    Time frame: Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28

  4. Apparent Plasma Terminal Half-life (t½) of ISL

    The t½ of ISL in plasma was determined at steady state.

    Time frame: Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28

  5. Apparent Total Clearance From Plasma (CL/F) of ISL

    The CL/F of ISL from plasma was determined at steady state.

    Time frame: Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28

  6. Apparent Volume of Distribution During Terminal Phase (Vz/F) of ISL

    The Vz/F of ISL was determined at steady state.

    Time frame: Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28

  7. AUC0-last of ISL-triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMCs)

    The AUC0-24 of ISL-TP in PBMCs was determined at steady state.

    Time frame: Pre-dose, and 4 and 24 hours post-dose on Day 28

  8. Cmax of ISL-TP in PBMCs

    The Cmax of ISL-TP in PBMCs was determined at steady state.

    Time frame: Pre-dose, and 4, and 24 hours post-dose on Day 28

  9. C24 of ISL-TP in PBMCs

    The C24 of ISL-TP in PBMCs was determined at steady state.

    Time frame: 24 hours post-dose on Day 28

  10. Number of Participants Experiencing ≥1 Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 24 weeks

  11. Number of Participants Discontinuing From Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Percentage of Virologically Suppressed (VS) Participants With HIV-1 Ribonucleic Acid (RNA) ≥50 Copies/mL

    The percentage of VS participants with HIV-1 RNA ≥50 copies/mL was determined at the central laboratory with an Abbott Real Time Polymerase Chain Reaction (PCR) assay with a lower limit of detection (LLOD) of 40 copies/mL.

    Time frame: Week 24

  2. Percentage of VS Participants With HIV-1 RNA <50 Copies/mL

    The percentage of VS participants with HIV-1 RNA \<50 copies/mL will be determined at the central laboratory with an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.

    Time frame: Week 24

  3. Percentage of Treatment Naive (TN) Participants With HIV-1 RNA <50 Copies/mL

    The percentage of TN participants with HIV-1 RNA \<50 copies/mL will be determined at the central laboratory with an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.

    Time frame: Week 24

  4. Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-cells in VS Participants

    CD4+ T-cell counts were measured by a central laboratory. Negative and positive results represent a decrease and increase, respectively, from baseline CD4+ T-cell counts.

    Time frame: Baseline (Day 1) and Week 24

  5. Change From Baseline in CD4+ T-cells in TN Participants

    CD4+ T-cell counts were measured by a central laboratory. Negative and positive results represent a decrease and increase, respectively, from baseline CD4+ T-cell counts.

    Time frame: Baseline (Day 1) and Week 24

  6. Incidence of Viral Drug Resistance to DOR

    The number of participants with viral drug resistance to DOR was determined.

    Time frame: Up to 24 weeks

  7. Incidence of Viral Drug Resistance to ISL

    The number of participants with viral drug resistance to ISL was determined.

    Time frame: Up to 24 weeks

  8. Palatability of DOR/ISL Tablet

    The palatability of the DOR/ISL tablet (whole or split) was assessed with a modified 5-point facial hedonic scale. Responses ranged from 1 ("very bad") to 5 ("very good"). Data show the number of VS and TN participants responding at each score at the designated time points.

    Time frame: Baseline (Day 1), Week 4, and Week 24

  9. Acceptability of DOR/ISL Tablet

    The acceptability of the DOR/ISL tablet (whole or split) was assessed. Acceptability was assessed by monitoring for refusing the tablet, throwing up or spitting out the tablet, and gagging on the tablet. Data show the number of VS and TN participants responding at each score at the designated time points.

    Time frame: Baseline (Day 1), Week 4, and Week 24

07

Results

Posted Feb 24, 2023

Participant flow

Pediatric participants who were ≥35 kg body weight and \<18 years of age were recruited at 18 study sites located in Italy, Russian Federation, Thailand, South Africa, and the United States.

Participant flow — Overall Study
MilestoneDOR/ISL: Virologically Suppressed CohortDOR/ISL: Treatment Naive Cohort
Started393
Completed222
Not completed171
Withdrew: Protocol violation10
Withdrew: Ongoing for safety monitoring141
Withdrew: Excluded from results due to informed consent issue20

Outcome measures

PrimaryArea Under the Plasma Drug Concentration-time Curve From 0 to 24 Hours Post-dose (AUC0-24) of Islatravir (ISL)

The AUC0-24 of ISL in plasma was determined at steady state.

Time frame:
Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28
Reported as:
Geometric mean · hr*µmol/L
Area Under the Plasma Drug Concentration-time Curve From 0 to 24 Hours Post-dose (AUC0-24) of Islatravir (ISL)
hr*µmol/LDOR/ISL: Virologically Suppressed Cohort
Area Under the Plasma Drug Concentration-time Curve From 0 to 24 Hours Post-dose (AUC0-24) of Islatravir (ISL)0.114 ± 28.6
PrimaryMaximum Plasma Concentration (Cmax) of ISL

The Cmax of ISL in plasma was determined at steady state.

Time frame:
Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28
Reported as:
Geometric mean · µmol/L
Maximum Plasma Concentration (Cmax) of ISL
µmol/LDOR/ISL: Virologically Suppressed Cohort
Maximum Plasma Concentration (Cmax) of ISL0.0245 ± 53.4
PrimaryTime to Reach Maximum Plasma Concentration (Tmax) of ISL

The Tmax of ISL in plasma was determined at steady state.

Time frame:
Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration (Tmax) of ISL
hoursDOR/ISL: Virologically Suppressed Cohort
Time to Reach Maximum Plasma Concentration (Tmax) of ISL1.00 (0.50 to 4.00)
PrimaryApparent Plasma Terminal Half-life (t½) of ISL

The t½ of ISL in plasma was determined at steady state.

Time frame:
Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28
Reported as:
Geometric mean · hours
Apparent Plasma Terminal Half-life (t½) of ISL
hoursDOR/ISL: Virologically Suppressed Cohort
Apparent Plasma Terminal Half-life (t½) of ISL16.5 ± 70.0
PrimaryApparent Total Clearance From Plasma (CL/F) of ISL

The CL/F of ISL from plasma was determined at steady state.

Time frame:
Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28
Reported as:
Geometric mean · L/hr
Apparent Total Clearance From Plasma (CL/F) of ISL
L/hrDOR/ISL: Virologically Suppressed Cohort
Apparent Total Clearance From Plasma (CL/F) of ISL22.5 ± 28.6
PrimaryApparent Volume of Distribution During Terminal Phase (Vz/F) of ISL

The Vz/F of ISL was determined at steady state.

Time frame:
Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution During Terminal Phase (Vz/F) of ISL
LitersDOR/ISL: Virologically Suppressed Cohort
Apparent Volume of Distribution During Terminal Phase (Vz/F) of ISL536 ± 61.1
PrimaryAUC0-last of ISL-triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMCs)

The AUC0-24 of ISL-TP in PBMCs was determined at steady state.

Time frame:
Pre-dose, and 4 and 24 hours post-dose on Day 28
Reported as:
Geometric mean · hr*pmol/10^6 cells
AUC0-last of ISL-triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMCs)
hr*pmol/10^6 cellsDOR/ISL: Virologically Suppressed Cohort
AUC0-last of ISL-triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMCs)52.3 ± 74.9
PrimaryCmax of ISL-TP in PBMCs

The Cmax of ISL-TP in PBMCs was determined at steady state.

Time frame:
Pre-dose, and 4, and 24 hours post-dose on Day 28
Reported as:
Geometric mean · pmol/10^6 cells
Cmax of ISL-TP in PBMCs
pmol/10^6 cellsDOR/ISL: Virologically Suppressed Cohort
Cmax of ISL-TP in PBMCs2.87 ± 91.6
PrimaryC24 of ISL-TP in PBMCs

The C24 of ISL-TP in PBMCs was determined at steady state.

Time frame:
24 hours post-dose on Day 28
Reported as:
Geometric mean · pmol/10^6 cells
C24 of ISL-TP in PBMCs
pmol/10^6 cellsDOR/ISL: Virologically Suppressed Cohort
C24 of ISL-TP in PBMCs2.05 ± 71.7
PrimaryNumber of Participants Experiencing ≥1 Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants Experiencing ≥1 Adverse Event (AE)
ParticipantsDOR/ISL: Virologically Suppressed CohortDOR/ISL: Treatment Naive Cohort
Number of Participants Experiencing ≥1 Adverse Event (AE)212
PrimaryNumber of Participants Discontinuing From Study Treatment Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants Discontinuing From Study Treatment Due to an AE
ParticipantsDOR/ISL: Virologically Suppressed CohortDOR/ISL: Treatment Naive Cohort
Number of Participants Discontinuing From Study Treatment Due to an AE00
SecondaryPercentage of Virologically Suppressed (VS) Participants With HIV-1 Ribonucleic Acid (RNA) ≥50 Copies/mL

The percentage of VS participants with HIV-1 RNA ≥50 copies/mL was determined at the central laboratory with an Abbott Real Time Polymerase Chain Reaction (PCR) assay with a lower limit of detection (LLOD) of 40 copies/mL.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Virologically Suppressed (VS) Participants With HIV-1 Ribonucleic Acid (RNA) ≥50 Copies/mL
percentage of participantsDOR/ISL: Virologically Suppressed Cohort
Percentage of Virologically Suppressed (VS) Participants With HIV-1 Ribonucleic Acid (RNA) ≥50 Copies/mL2.9 (0.1 to 15.3)
SecondaryPercentage of VS Participants With HIV-1 RNA <50 Copies/mL

The percentage of VS participants with HIV-1 RNA \<50 copies/mL will be determined at the central laboratory with an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of VS Participants With HIV-1 RNA <50 Copies/mL
percentage of participantsDOR/ISL: Virologically Suppressed Cohort
Percentage of VS Participants With HIV-1 RNA <50 Copies/mL94.1 (80.3 to 99.3)
SecondaryPercentage of Treatment Naive (TN) Participants With HIV-1 RNA <50 Copies/mL

The percentage of TN participants with HIV-1 RNA \<50 copies/mL will be determined at the central laboratory with an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Treatment Naive (TN) Participants With HIV-1 RNA <50 Copies/mL
percentage of participantsDOR/ISL: Treatment Naive Cohort
Percentage of Treatment Naive (TN) Participants With HIV-1 RNA <50 Copies/mL100.0 (2.5 to 100.0)
SecondaryChange From Baseline in Cluster of Differentiation 4+ (CD4+) T-cells in VS Participants

CD4+ T-cell counts were measured by a central laboratory. Negative and positive results represent a decrease and increase, respectively, from baseline CD4+ T-cell counts.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · cells/mm^3
Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-cells in VS Participants
cells/mm^3DOR/ISL: Virologically Suppressed Cohort
Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-cells in VS Participants-112.1 (-175.8 to -48.4)
SecondaryChange From Baseline in CD4+ T-cells in TN Participants

CD4+ T-cell counts were measured by a central laboratory. Negative and positive results represent a decrease and increase, respectively, from baseline CD4+ T-cell counts.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Number · cells/mm^3
Change From Baseline in CD4+ T-cells in TN Participants
cells/mm^3DOR/ISL: Treatment Naive Cohort
Change From Baseline in CD4+ T-cells in TN Participants705.0 (NA to NA)
SecondaryIncidence of Viral Drug Resistance to DOR

The number of participants with viral drug resistance to DOR was determined.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Incidence of Viral Drug Resistance to DOR
ParticipantsDOR/ISL: Virologically Suppressed CohortDOR/ISL: Treatment Naive Cohort
Incidence of Viral Drug Resistance to DOR00
SecondaryIncidence of Viral Drug Resistance to ISL

The number of participants with viral drug resistance to ISL was determined.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Incidence of Viral Drug Resistance to ISL
ParticipantsDOR/ISL: Virologically Suppressed CohortDOR/ISL: Treatment Naive Cohort
Incidence of Viral Drug Resistance to ISL00
SecondaryPalatability of DOR/ISL Tablet

The palatability of the DOR/ISL tablet (whole or split) was assessed with a modified 5-point facial hedonic scale. Responses ranged from 1 ("very bad") to 5 ("very good"). Data show the number of VS and TN participants responding at each score at the designated time points.

Time frame:
Baseline (Day 1), Week 4, and Week 24
Reported as:
Count of participants · Participants
Palatability of DOR/ISL Tablet
ParticipantsDOR/ISL: Virologically Suppressed CohortDOR/ISL: Treatment Naive Cohort
Very Bad - Day 100
Very Bad - Week 400
Very Bad - Week 2420
Bad - Day 100
Bad - Week 400
Bad - Week 2430
Neither good or bad - Day 1120
Neither good or bad - Week 4110
Neither good or bad - Week 2480
Good - Day 192
Good - Week 4112
Good - Week 2451
Very Good - Day 1161
Very Good - Week 4151
Very Good - Week 2440
SecondaryAcceptability of DOR/ISL Tablet

The acceptability of the DOR/ISL tablet (whole or split) was assessed. Acceptability was assessed by monitoring for refusing the tablet, throwing up or spitting out the tablet, and gagging on the tablet. Data show the number of VS and TN participants responding at each score at the designated time points.

Time frame:
Baseline (Day 1), Week 4, and Week 24
Reported as:
Count of participants · Participants
Acceptability of DOR/ISL Tablet
ParticipantsDOR/ISL: Virologically Suppressed CohortDOR/ISL: Treatment Naive Cohort
Refusing - Day 100
Refusing - Week 400
Refusing - Week 2400
Throwing Up/Spitting Out - Day 100
Throwing Up/Spitting Out - Week 400
Throwing Up/Spitting Out - Week 2400
Gagging - Day 100
Gagging - Week 400
Gagging - Week 2410

Adverse events

Collected over Up to approximately 16 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DOR/ISL: Virologically Suppressed Cohort0/37 (0%)1/37 (2.7%)13/37 (35.1%)
DOR/ISL: Treatment Naive Cohort0/3 (0%)0/3 (0%)2/3 (66.7%)
DOR/ISL: Virologically Suppressed Cohort Extended Monitoring0/14 (0%)0/14 (0%)12/14 (85.7%)
DOR/ISL: Treatment Naive Cohort Extended Monitoring0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventDOR/ISL: Virologically Suppressed CohortDOR/ISL: Treatment Naive CohortDOR/ISL: Virologically Suppressed Cohort Extended MonitoringDOR/ISL: Treatment Naive Cohort Extended Monitoring
ConcussionInjury, poisoning and procedural complications1/370/30/140/1
Most frequent other events
Showing 10 of 41
Most frequent other events
EventDOR/ISL: Virologically Suppressed CohortDOR/ISL: Treatment Naive CohortDOR/ISL: Virologically Suppressed Cohort Extended MonitoringDOR/ISL: Treatment Naive Cohort Extended Monitoring
COVID-19Infections and infestations0/370/31/141/1
DyspepsiaGastrointestinal disorders0/371/30/140/1
PyrexiaGeneral disorders2/371/31/140/1
Vaccination site painGeneral disorders1/371/31/140/1
DizzinessNervous system disorders2/371/31/140/1
HeadacheNervous system disorders2/371/31/140/1
UrticariaSkin and subcutaneous tissue disorders0/371/30/140/1
CoughRespiratory, thoracic and mediastinal disorders3/370/34/140/1
Upper respiratory tract infectionInfections and infestations3/370/33/140/1
Oropharyngeal painRespiratory, thoracic and mediastinal disorders4/370/33/140/1

Baseline characteristics

Age, Continuous
Age, Continuous(years)DOR/ISL: Virologically Suppressed CohortDOR/ISL: Treatment Naive CohortTotal
Mean14.7 ± 2.215.7 ± 1.514.8 ± 2.1
Sex: Female, Male
Sex: Female, Male(Participants)DOR/ISL: Virologically Suppressed CohortDOR/ISL: Treatment Naive CohortTotal
Female14115
Male23225
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DOR/ISL: Virologically Suppressed CohortDOR/ISL: Treatment Naive CohortTotal
Hispanic or Latino101
Not Hispanic or Latino35338
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DOR/ISL: Virologically Suppressed CohortDOR/ISL: Treatment Naive CohortTotal
American Indian or Alaska Native000
Asian9312
Native Hawaiian or Other Pacific Islander000
Black or African American20020
White808
More than one race000
Unknown or Not Reported000
08

Study locations

17 sites
  • Children's National Medical Center ( Site 1816)
    Washington, District of Columbia 20010, United States
  • Emory Children's Center ( Site 1805)
    Atlanta, Georgia 30322, United States
  • Johns Hopkins University ( Site 1800)
    Baltimore, Maryland 21287, United States
  • Duke University ( Site 1807)
    Durham, North Carolina 27705, United States
  • Azienda Ospedaliera Luigi Sacco ( Site 1300)
    Milano, 20157, Italy
  • IRCCS Ospedale Pediatrico Bambino Gesu ( Site 1301)
    Roma, 00165, Italy
  • Krasnoyarsk Regional Center for Prevention and Control of AIDS ( Site 1507)
    Krasnoyarsk, Krasnoyarskiy Kray 660049, Russian Federation
  • Infectious Clinical Hospital #2 ( Site 1501)
    Moscow, Moskva 105275, Russian Federation
  • FGU Republican Clinical Infectious Hospital of Roszdrav ( Site 1500)
    Saint Petersburg, Sankt-Peterburg 196645, Russian Federation
  • Saratov Regional Clinical Center for Prophylaxis and Control of AIDS ( Site 1505)
    Saratov, Saratovskaya Oblast 410009, Russian Federation
  • Perinatal HIV Research Unit ( Site 1902)
    Johannesburg, Gauteng 1864, South Africa
  • Wits Reproductive Health and HIV Institute (WRHI) ( Site 1903)
    Johannesburg, Gauteng 2000, South Africa
  • Empilweni Services and Research Unit ( Site 1904)
    Johannesburg, Gauteng 2093, South Africa
  • King Edward Hospital ( Site 1900)
    Durban, Kwazulu-Natal 4001, South Africa
  • Chulalongkorn University ( Site 1602)
    Bangkok, Krung Thep Maha Nakhon 10330, Thailand
  • Siriraj Hospital ( Site 1601)
    Bangkok, Krung Thep Maha Nakhon 10700, Thailand
  • Research Institute for Health Sciences ( Site 1603)
    Chiang Mai, 50200, Thailand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Dec 2021, 12 months.

Results were first posted in Feb 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2020
First posted
Mar 4, 2020
StartActual
Nov 26, 2020
Primary completionActual
Dec 21, 2021
CompletionActual
Jan 25, 2023
Results first posted
Feb 24, 2023
Last update
Jan 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04295772
Responsible party
Sponsor
First posted
Mar 4, 2020
Start date
Nov 26, 2020
Primary completion
Dec 21, 2021
Completion
Jan 25, 2023
Results posted
Feb 24, 2023
Last update
Jan 31, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doravirine · Islatravir

Start the discussion